Rating Change
Guggenheim reiterated its Buy rating on Zura Bio Limited (NASDAQ:ZURA) on August 12, 2026.
Guggenheim reiterated its Buy rating on Zura Bio Limited (NASDAQ:ZURA) on August 12, 2026.

At publication ·
Zura Bio Limited (NASDAQ:ZURA) · reiterate
At a glance
Guggenheim reiterated its Buy rating on Zura Bio Limited (NASDAQ:ZURA) on August 12, 2026.
Zura Bio Limited operates in the Healthcare sector. The stock currently trades at $5.78 with a market capitalization of $263.3M.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Zura Bio Limited.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Wedbush | Outperform | N/A |
| Aug 12, 2026 | Guggenheim | Buy | N/A |
| Jul 08, 2026 | William Blair | Outperform | N/A |
| Jul 01, 2026 | Wedbush | Outperform | N/A |
| Mar 23, 2026 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ZURA Stock Page
A rating of Buy from Guggenheim reflects the analyst's outlook on Zura Bio Limited (NASDAQ:ZURA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ZURA forecast page.
Current market data
NASDAQ · ZURA
$5.38
Down: -$0.33 · -5.78%
Live quote updated
Keep reading